Faeth Therapeutics (FTH) EBT (2020 - 2026)

Faeth Therapeutics (FTH) has reported EBT for 7 consecutive years, with -$16.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 228.79% year-over-year to -$16.1 million; the trailing twelve-month figure through Jun 2026 stood at -$196.1 million (down 620.71% YoY), and the FY2025 full-year result was -$21.1 million, up 30.09% from the prior year.
• EBT improved to -$16.1 million in Q2 2026 per FTH's latest filing, from -$170.7 million in the prior quarter.
• Across five years, EBT topped out at -$4.6 million in Q3 2025 and bottomed at -$170.7 million in Q1 2026.
• Historically, EBT has averaged -$18.1 million across 5 years, with a median of -$8.2 million in 2024.
• The sharpest annual moves came in 2023 and 2026: EBT soared 48.7% in 2023, then slumped 2244.12% in 2026.
• Over 5 years, EBT stood at -$12.2 million in 2022, then jumped by 39.94% to -$7.3 million in 2023, then slipped by 5.74% to -$7.8 million in 2024, then soared by 39.03% to -$4.7 million in 2025, then tumbled by 240.45% to -$16.1 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$16.1 million, -$170.7 million, and -$4.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.